Startup lands $20 million for AI-powered tech that collects and analyzes multiple digital health signals for a ‘real-time’ view of health.
HealthTech startup Percipio Health has raised $20 million in a Series A funding round and officially launched its AI-powered population health monitoring platform. The company claims its platform leverages only a smartphone to collect and analyze multiple health signals and provide a comprehensive, real-time view of an individual’s health.
While many in longevity are calling for radical change to the current healthcare model, Percipio is focused on how the existing model can be improved – for patients, providers and payers alike. The company is addressing the current limitations of remote patient monitoring, typically limited to the top 1% of at-risk populations, to offer a scalable and low-cost alternative that accommodates broader populations and addresses the polychronic nature of chronic illnesses.
Chronic conditions like kidney disease, mild cognitive impairment and early-stage hypertension often remain undiagnosed until they progress to advanced stages, incurring significant healthcare costs and impacting patient outcomes. By providing predictive insights, Percipio aims to enable the early identification and intervention that could prevent disease progression, reduce healthcare costs, and improve quality of life.
Developed by digital health entrepreneurs Eric Rock and David Lucas, the company’s platform combines both vision-based and vocal AI biomarkers to monitor vital signs, medication adherence, brain health, and social determinants of health. Using the camera on a smartphone, Percipio captures and analyzes health signals such as heart rate and respiratory rate. It assesses brain health through short voice recordings and monitors medication adherence via photo journaling.
“With Percipio, we’re addressing very specific and strategic technology gaps that have been inhibiting value-based care from fulfilling its promise,” said Lucas, Percipio’s Chief Strategy Officer. “Payers and providers can now reach and understand a much broader population, of both rising and high risk, to ensure they receive the proactive attention, assessment and interventions they need, resulting in lower costs of care and more optimal outcomes.”
The funding was raised from investors including UPMC Enterprises, WAVE Ventures, Labcorp, and First Trust Capital Partners, LLC.
WAVE Ventures’ Dr Cameron Powell, an early pioneer of remote patient monitoring, said that the goal of the technology is all about giving a clinician the right information about the right patient at the right time to affect the right outcome.
“We’ve all been trying to do that for decades,” he said. “Now, with Percipio, this need can be accomplished at scale, at lower cost, with higher fidelity, transparency, and visibility of the data. Percipio’s team has proven and repeated experience delivering advanced technology that leads to better care and outcomes, only this time it extends to the entire population.”
“Asynchronous monitoring is among the most powerful tools for the future of healthcare, enabled by the efficiencies of AI,” said Dr Andrew R Watson, Senior Medical Advisor at UPMC Enterprises. “This ability to make the patient’s phone a pivotal part of health care may provide powerful health insights, second only to genetics.”
